Objective The effectiveness of sugemalimab vs. placebo in post-chemoradiotherapy patients with locally advanced, unresectable stage III NSCLC has been demonstrated and approved by China National Medic
Abstract The objective of this study was to analyze the indiscriminate use of medical technologies could cause damage. The methodology involved a literature review of the use of technologies that can
